CJ negotiating to merger Hanil Pharm via stake acquisition

Published: 2003-12-26 06:57:00

Updated: 2003-12-26 06:57:00

CJ said on December 22 that it submitted a letter of intent to participate in the bidding as part of its efforts to acquire insolvent Hanil Pharm's stake and as a result, CJ was named a preferred bidder on December 19.

The company further confirmed that the letter is now under negotiation with...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK